Histone deacetylases (HDACs) regulate gene transcription by removing acetyl groups from lysines. However, their dysregulation often promotes cancer progression. Currently approved HDAC inhibitors face significant challenges, including limited isoform selectivity and modest efficacy in solid tumors. To address these issues, researchers have developed novel HDAC6 inhibitors known as biphenyl-substituted uracil-based hydroxamic acids (UBHAs).

By systematically modifying cap groups and linkers, the team synthesized a series of potent compounds. Consequently, several UBHAs achieved nanomolar inhibition, specifically targeting HDAC6 while reducing activity toward class I isoforms. This selectivity is essential for improving patient outcomes and reducing systemic toxicity. Moreover, structure-activity relationships revealed that biphenyl moieties and four-carbon linkers significantly enhance molecular potency.

Potential Applications of Novel HDAC6 Inhibitors

The study identified two lead candidates that effectively reduced cancer cell viability at submicromolar doses. Remarkably, these molecules spared noncancerous cells, suggesting a high therapeutic index. In U937 leukemia cells, the treatment promoted cell-cycle arrest and apoptosis. Additionally, it increased H3K9 and α-tubulin acetylation while modulating microRNAs associated with cell death. Furthermore, these findings highlight the potential for UBHAs to serve as both therapeutics and biological probes.

In prostate cancer models, the leads inhibited the proliferation of both AR-positive and AR-negative cells. These compounds upregulated the tumor suppressor p21 and downregulated the anti-apoptotic protein Bcl-2. Because these inhibitors show efficacy in both leukemia and solid tumor models, they represent a versatile advancement in epigenetic therapy. Future clinical investigations will likely explore their role in combination treatments or as standalone agents.

Frequently Asked Questions

What makes these new inhibitors different from existing HDAC drugs?

These novel compounds offer higher selectivity for the HDAC6 isoform. Unlike pan-HDAC inhibitors, they target specific enzymes, which potentially reduces side effects and improves efficacy in solid tumors like prostate cancer.

How do UBHAs induce cancer cell death?

UBHAs trigger apoptosis by modulating genes like p21 and Bcl-2. They also increase the acetylation of histones and tubulin, leading to cell-cycle arrest and programmed cell death in leukemia and prostate cancer cells.

Are these compounds safe for healthy cells?

Preliminary research indicates that these lead candidates reduce the viability of cancer cells at submicromolar doses while largely sparing noncancerous cells, suggesting a favorable safety profile.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional recommendation. Always consult with a qualified healthcare provider regarding any medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.

References

Fiorentino F et al. Development of Biphenyl-Substituted Uracil-Based Hydroxamic Acids (UBHAs) as Potent HDAC Inhibitors with Pro-Apoptotic Activity in Leukemia and Prostate Cancer Cells. J Med Chem. 2026 Apr 30. doi: 10.1021/acs.jmedchem.5c02737. PMID: 42059134.

Dallavalle S, et al. Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors. Eur J Med Chem. 2009 May;44(5):1900-12.

Rivas MA, et al. Understanding Failure and Improving Treatment Using HDAC Inhibitors for Prostate Cancer. Cancers (Basel). 2020 Jan 30;12(2):331.